Indoleamine 2, 3-Dioxygenase Promotes Aryl Hydrocarbon Receptor-Dependent Differentiation Of Regulatory B Cells in Lung Cancer.
Animals
B-Lymphocytes, Regulatory
/ immunology
Carcinoma, Lewis Lung
/ immunology
Cell Differentiation
/ immunology
Indoleamine-Pyrrole 2,3,-Dioxygenase
/ immunology
Mice
Myeloid-Derived Suppressor Cells
/ immunology
Receptors, Aryl Hydrocarbon
/ immunology
Tryptophan
/ metabolism
Tumor Microenvironment
/ immunology
Breg cells
IDO
L-Kynurenine
MDSC (myeloid-derived suppressor cells)
TME (tumor microenvironment)
aryl hydrocarbon receptor (AhR)
immunosuppression
lung cancer
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
26
07
2021
accepted:
02
11
2021
entrez:
6
12
2021
pubmed:
7
12
2021
medline:
17
12
2021
Statut:
epublish
Résumé
Regulatory B cells (Breg) are IL-10 producing subsets of B cells that contribute to immunosuppression in the tumor microenvironment (TME). Breg are elevated in patients with lung cancer; however, the mechanisms underlying Breg development and their function in lung cancer have not been adequately elucidated. Herein, we report a novel role for Indoleamine 2, 3- dioxygenase (IDO), a metabolic enzyme that degrades tryptophan (Trp) and the Trp metabolite L-kynurenine (L-Kyn) in the regulation of Breg differentiation in the lung TME. Using a syngeneic mouse model of lung cancer, we report that Breg frequencies significantly increased during tumor progression in the lung TME and secondary lymphoid organs, while Breg were reduced in tumor-bearing IDO deficient mice (IDO
Identifiants
pubmed: 34867973
doi: 10.3389/fimmu.2021.747780
pmc: PMC8640488
doi:
Substances chimiques
Indoleamine-Pyrrole 2,3,-Dioxygenase
0
Receptors, Aryl Hydrocarbon
0
Tryptophan
8DUH1N11BX
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
747780Informations de copyright
Copyright © 2021 Tousif, Wang, Jackson, Hough, Strenkowski, Athar, Thannickal, McCusker, Ponnazhagan and Deshane.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Immunol. 2010 May 1;184(9):4789-800
pubmed: 20368280
Oral Oncol. 2016 Feb;53:27-35
pubmed: 26631955
Immunol Lett. 2007 Aug 15;111(2):69-75
pubmed: 17644189
EMBO J. 2017 Jan 4;36(1):116-128
pubmed: 27875245
J Immunol. 2015 Sep 1;195(5):2374-82
pubmed: 26216892
J Immunol. 2013 Mar 15;190(6):2575-84
pubmed: 23408836
BMC Cancer. 2014 May 15;14:335
pubmed: 24886161
Int Immunol. 1990;2(9):821-32
pubmed: 1703785
Immunity. 2002 Feb;16(2):219-30
pubmed: 11869683
Cancer Cell. 2005 May;7(5):411-23
pubmed: 15894262
Science. 2011 Mar 25;331(6024):1565-70
pubmed: 21436444
J Immunol. 2005 Oct 1;175(7):4180-3
pubmed: 16177055
Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):19961-6
pubmed: 21041655
Oncotarget. 2016 Nov 15;7(46):75407-75424
pubmed: 27705910
J Clin Invest. 2007 May;117(5):1147-54
pubmed: 17476344
Cancer Res. 2006 Jan 15;66(2):1123-31
pubmed: 16424049
J Immunol. 2010 May 1;184(9):4801-9
pubmed: 20368271
Annu Rev Immunol. 2012;30:221-41
pubmed: 22224776
Blood. 2008 Aug 15;112(4):1205-13
pubmed: 18495955
Int J Mol Sci. 2018 May 15;19(5):
pubmed: 29762501
Cancer Cell. 2009 Aug 4;16(2):91-102
pubmed: 19647220
Int J Biochem Cell Biol. 2014 Dec;57:63-8
pubmed: 25450457
Inflamm Res. 2009 Jul;58(7):345-57
pubmed: 19262989
J Clin Invest. 2011 Nov;121(11):4268-80
pubmed: 22019587
J Immunol. 1998 Dec 15;161(12):6977-84
pubmed: 9862733
Toxicol Appl Pharmacol. 1990 Aug;105(1):26-36
pubmed: 2168100
J Immunol. 2016 Dec 1;197(11):4493-4503
pubmed: 27799309
Oncoimmunology. 2013 Jul 1;2(7):e25443
pubmed: 24073382
J Immunol. 2008 Oct 15;181(8):5791-802
pubmed: 18832739
Toxicol In Vitro. 2015 Mar;29(2):329-36
pubmed: 25500125
Nature. 2011 Oct 05;478(7368):197-203
pubmed: 21976023
J Leukoc Biol. 2013 May;93(5):811-8
pubmed: 23434518
Infect Immun. 2004 Sep;72(9):5041-51
pubmed: 15321997
J Immunol. 2008 May 1;180(9):5771-7
pubmed: 18424693
Oncogene. 1999 Nov 22;18(49):6853-66
pubmed: 10602461
Nat Rev Immunol. 2009 Mar;9(3):162-74
pubmed: 19197294
J Immunol. 2007 Dec 1;179(11):7225-32
pubmed: 18025164
Cancer Treat Rev. 2014 May;40(4):558-66
pubmed: 24176790
J Transl Med. 2014 Nov 11;12:304
pubmed: 25381811
J Immunol. 1974 Dec;113(6):1716-25
pubmed: 4279260
Mol Immunol. 2010 Nov-Dec;48(1-3):1-8
pubmed: 20950861
Cancer Res. 2006 Aug 1;66(15):7741-7
pubmed: 16885377
J Immunol. 2008 Apr 1;180(7):4763-73
pubmed: 18354200
Immunity. 2015 Apr 21;42(4):607-12
pubmed: 25902480
Proc Natl Acad Sci U S A. 2007 Aug 28;104(35):14080-5
pubmed: 17715067
Cancer Immunol Immunother. 2009 Jan;58(1):153-7
pubmed: 18418598
Proc Natl Acad Sci U S A. 2007 May 1;104(18):7552-7
pubmed: 17460043
Hum Immunol. 2016 Jan;77(1):84-89
pubmed: 26527508
Nat Rev Neurosci. 2012 Jul;13(7):465-77
pubmed: 22678511
J Immunol. 2018 Jul 1;201(1):278-295
pubmed: 29752311
Mol Immunol. 2014 Dec;62(2):296-304
pubmed: 24556109
J Immunol. 2006 Jun 1;176(11):6752-61
pubmed: 16709834
Nat Med. 2004 Sep;10(9):942-9
pubmed: 15322536
Cancer Res. 2013 Nov 15;73(22):6609-20
pubmed: 24085788
Cancer Res. 2013 Apr 15;73(8):2468-79
pubmed: 23384943
Annu Rev Genomics Hum Genet. 2009;10:45-61
pubmed: 19405848
Cancer Lett. 2014 Dec 28;355(2):264-72
pubmed: 25301451
J Exp Med. 2003 Feb 17;197(4):489-501
pubmed: 12591906
J Immunother. 2004 Jul-Aug;27(4):273-81
pubmed: 15235388
Nature. 1974 Oct 11;251(5475):550-1
pubmed: 4547522
J Pharmacol Exp Ther. 1998 Dec;287(3):1113-8
pubmed: 9864300
Cancer Res. 2011 May 15;71(10):3505-15
pubmed: 21444674
J Immunol. 2010 Sep 15;185(6):3190-8
pubmed: 20720200
Nat Med. 2014 Nov;20(11):1334-9
pubmed: 25326801
J Immunol. 2009 Aug 1;183(3):1518-22
pubmed: 19570829
Proc Natl Acad Sci U S A. 2015 Aug 25;112(34):10774-9
pubmed: 26261340
J Immunol. 2009 Apr 15;182(8):4499-506
pubmed: 19342621
Nat Rev Cancer. 2006 Jan;6(1):24-37
pubmed: 16397525
Cancer Immunol Immunother. 2013 Jan;62(1):87-99
pubmed: 22772949
Cell Immunol. 1991 Nov;138(1):35-43
pubmed: 1913841
Int J Tryptophan Res. 2010;3:113-20
pubmed: 22084593
Eur J Immunol. 2014 Nov;44(11):3307-19
pubmed: 25113564
Int Rev Immunol. 2012 Jun;31(3):177-83
pubmed: 22587019
Eur J Immunol. 1992 Mar;22(3):711-7
pubmed: 1547817
Nat Commun. 2016 Jul 06;7:12150
pubmed: 27381735
Blood. 2013 Aug 15;122(7):1105-13
pubmed: 23757729
Immunity. 2016 Apr 19;44(4):913-923
pubmed: 27096320
J Exp Med. 2017 Jan;214(1):197-208
pubmed: 28011866
Cent Eur J Immunol. 2015;40(2):263-5
pubmed: 26557042
Nat Immunol. 2002 Oct;3(10):944-50
pubmed: 12244307
J Immunol. 2009 Jun 1;182(11):6709-17
pubmed: 19454665
Trends Immunol. 2008 Jan;29(1):34-40
pubmed: 18289504
Cancer Res. 2006 Jul 1;66(13):6807-15
pubmed: 16818658
Int J Cancer. 2005 Nov 20;117(4):574-86
pubmed: 15912532
J Immunol. 2013 Sep 1;191(5):2780-2795
pubmed: 23918988
Proc Natl Acad Sci U S A. 2010 Nov 30;107(48):20768-73
pubmed: 21068375
CA Cancer J Clin. 2013 Jan;63(1):11-30
pubmed: 23335087
Proc Natl Acad Sci U S A. 2011 Jun 28;108(26):10662-7
pubmed: 21670304
Arthritis Rheumatol. 2016 Nov;68(11):2717-2727
pubmed: 27214349
Nat Med. 2003 Oct;9(10):1269-74
pubmed: 14502282